Transparency and reporting characteristics of randomized controlled trials with Chinese herbal medicine formulas interventions
Juan Wang1,2, Dongni Shi2, Yaochen Wang2, Xuanqi Zhang2, Han Li2, Xihong Wang3, Shufeng Luo2, Lihan Hu2, Jiashuai Deng4, Lin Zhang3, Chung Tai Lau1,5, Chung Wah Cheng1,5, Fei Han6, Ji Li6, Ping Wang7, Aiping Lyu1,2,5, Zhaoxiang Bian1,2,5,8, Xuan Zhang1,2,5,8()
1. Institute for Research and Continuing Education, Hong Kong Baptist University, Shenzhen 518057, China 2. Chinese EQUATOR Centre, Hong Kong Baptist University, HKSAR 999077, China 3. School of Traditional Chinese Medicine, Tianjin University of Chinese Medicine, Tianjin 301617, China 4. School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100105, China 5. School of Chinese Medicine, Hong Kong Baptist University, HKSAR 999077, China 6. Department of Pediatrics, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China 7. Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China 8. Centre for Chinese Herbal Medicine Drug Development, Hong Kong Baptist University, HKSAR 999077, China
CW Cheng, TX Wu, HC Shang, YP Li, DG Altman, D Moher, ZX; CONSORT-CHM Formulas 2017 Group Bian. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: recommendations, explanation, and elaboration. Ann Intern Med 2017; 167(2): 112–121 https://doi.org/10.7326/M16-2977
2
M Li, B Zhou, L Zhou, L Li. Reporting quality of randomized controlled trials for the treatment of eczema with Chinese patent medicine based on the CONSORT-CHM Formulas 2017. Evid Based Complement Alternat Med 2020; 2020: 2949125
3
XJ Zhang, YJ Wang, X Lu, PJ Ying, SY Qian, J Liang, GQ Zheng. The quality of reporting of randomized controlled trials of HuatuoZaizao pill for stroke. Front Pharmacol 2023; 13: 1106957 https://doi.org/10.3389/fphar.2022.1106957
4
XW Yu, J Guo, W Yu, B Yan, G Du, H Wang, J Zhang. Quality evaluation and consideration of randomized controlled clinical trials report on traditional Chinese medicine (TCM) treatment of prostate cancer. J Xinjiang Med Univ (Xinjiang Yi Ke Da Xue Xue Bao) 2022; 45(7): 776–779
5
Y Tian, D Guo, W Peng, P Zhou, YC Liu, MX Fan, F Lu. Evaluation of the clinical evidence-body of Chinese patent medicine in the treatment of essential hypertension. Chin J Hypertens (Zhonghua Gao Xue Ya Za Zhi) 2022; 30(10): 956–963
6
B Yan, SJ Liu, YJ Deng, J Guo, J Guo. Research characteristics and quality evaluation of randomized controlled trial report of Chinese patent drug in the treatment of male infertility. Chin J Hum Sex (Zhongguo Xing Ke Xue) 2023; 32(2): 109–113
7
YQ Xu, QH Cai, H Wang, SY Hu. Evaluation on methodological and reporting quality of randomized controlled trials of Chinese patent medicines for acute upper respiratory infection in children based on Cochrane risk bias assessment tool and CONSORT-CHM Formulas. Tianjin J Tradit Chin Med (Tianjin Zhong Yi Yao) 2020; 37(3): 308–312
8
MJ Page, JE McKenzie, PM Bossuyt, I Boutron, TC Hoffmann, CD Mulrow, L Shamseer, JM Tetzlaff, EA Akl, SE Brennan, R Chou, J Glanville, JM Grimshaw, A Hróbjartsson, MM Lalu, T Li, EW Loder, E Mayo-Wilson, S McDonald, LA McGuinness, LA Stewart, J Thomas, AC Tricco, VA Welch, P Whiting, D Moher. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71 https://doi.org/10.1136/bmj.n71
9
J Wang, CW Cheng, Y Jiao, D Shi, Y Wang, H Li, N Wang, X Wang, Y Li, F Liang, S Luo, F Han, J Li, P Wang, A Lyu, Z Bian, X Zhang. Evaluation of compliance of CONSORT-CHM formula 2017 in randomized controlled trials of Chinese herbal medicine formulas: protocol of a five-year review. Front Pharmacol 2024; 15: 1287262 https://doi.org/10.3389/fphar.2024.1287262
10
KF Schulz, DG Altman, D; CONSORT Group Moher. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c332 https://doi.org/10.1136/bmj.c332
11
Group DSM. The Russian pharmaceutical market. 2014. Available at the website of dsm. ru/docs/analytics/spravka_may_2014.pdf (in Russian)
12
Ipsos Reid. Natural Health Product Tracking Survey – 2010. Final Report. Prepared for Health Canada. 2011. Available at the related website
13
HL Wang, H Zeng, MB Xu, XL Zhou, PQ Rong, TY Jin, Q Wang, GQ Zheng. Efficacy and safety of Chinese herbal medicine for primary intracerebral hemorrhage: a systematic review of randomized controlled trials. Front Pharmacol 2019; 10: 1139 https://doi.org/10.3389/fphar.2019.01139
14
Y Wang, Y Liu, X Yan, D Wang. An overview of systematic reviews on the effectiveness of Wenxin Keli in the treatment of atrial fibrillation. Evid Based Complement Alternat Med 2022; 2022: 6973151 https://doi.org/10.1155/2022/6973151
15
J Hu, M Cheng, Y Li, B Shi, S He, Z Yao, J Jiang, H Yu, Z He, Y Zhao, H Zheng, B Hua, R Liu. Ginseng-containing traditional medicine preparations in combination with fluoropyrimidine-based chemotherapy for advanced gastric cancer: a systematic review and meta-analysis. PLoS One 2023; 18(4): e0284398 https://doi.org/10.1371/journal.pone.0284398
16
World Health Organization. Traditional Medicine Strategy (2002–2005). Licence: WHO/EDM/TRM/2002.1. Available at the website of WHO
17
QJ Pan, JB Zeng, CJ Wan, BL Wu. Based on Cochrane bias evaluation tool and consort traditional Chinese medicine compound evaluation Buyang Huanwu Decoction in the treatment of chronic heart failure randomized controlled trial methodology and report quality evaluation. J Jiangxi Univ Chin Med (Jiangxi Zhong Yi Yao Da Xue Xue Bao) 2022; 34(05): 42–46,49
18
C Liu, DA Guo, L Liu. Quality transitivity and traceability system of herbal medicine products based on quality markers. Phytomedicine 2018; 44: 247–257 https://doi.org/10.1016/j.phymed.2018.03.006
19
World Health Organization. WHO international standard terminologies on traditional Chinese medicine. 2022. Licence: CC BY-NC-SA 3.0 IGO. Available at the website of WHO
20
E Cobo, J Cortés, JM Ribera, F Cardellach, A Selva-O’Callaghan, B Kostov, L García, L Cirugeda, DG Altman, JA González, JA Sànchez, F Miras, A Urrutia, V Fonollosa, C Rey-Joly, M Vilardell. Effect of using reporting guidelines during peer review on quality of final manuscripts submitted to a biomedical journal: masked randomised trial. BMJ 2011; 343: d6783 https://doi.org/10.1136/bmj.d6783
21
L Turner, L Shamseer, DG Altman, L Weeks, J Peters, T Kober, S Dias, KF Schulz, AC Plint, D Moher. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Libr 2012; 11: MR000030 https://doi.org/10.1002/14651858.MR000030.pub2
